NASDAQ:UNCY - Nasdaq - US90466Y1038 - Common Stock - Currency: USD
0.6169
+0.01 (+1.15%)
The current stock price of UNCY is 0.6169 USD. In the past month the price decreased by -1.6%. In the past year, price decreased by -65.54%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. The company is headquartered in Los Altos, California and currently employs 14 full-time employees. The company went IPO on 2021-06-17. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
UNICYCIVE THERAPEUTICS INC
4300 El Camino Real, Suite 210
Los Altos CALIFORNIA US
CEO: Shalabh Gupta
Employees: 14
Company Website: https://unicycive.com/
Investor Relations: https://unicycive.com/investors/
Phone: 16503840642
The current stock price of UNCY is 0.6169 USD. The price increased by 1.15% in the last trading session.
The exchange symbol of UNICYCIVE THERAPEUTICS INC is UNCY and it is listed on the Nasdaq exchange.
UNCY stock is listed on the Nasdaq exchange.
12 analysts have analysed UNCY and the average price target is 5.61 USD. This implies a price increase of 809.39% is expected in the next year compared to the current price of 0.6169. Check the UNICYCIVE THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
UNICYCIVE THERAPEUTICS INC (UNCY) has a market capitalization of 64.03M USD. This makes UNCY a Micro Cap stock.
UNICYCIVE THERAPEUTICS INC (UNCY) currently has 14 employees.
UNICYCIVE THERAPEUTICS INC (UNCY) has a support level at 0.56 and a resistance level at 0.62. Check the full technical report for a detailed analysis of UNCY support and resistance levels.
The Revenue of UNICYCIVE THERAPEUTICS INC (UNCY) is expected to decline by -100% in the next year. Check the estimates tab for more information on the UNCY EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
UNCY does not pay a dividend.
UNICYCIVE THERAPEUTICS INC (UNCY) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
The outstanding short interest for UNICYCIVE THERAPEUTICS INC (UNCY) is 0.84% of its float. Check the ownership tab for more information on the UNCY short interest.
ChartMill assigns a technical rating of 2 / 10 to UNCY. When comparing the yearly performance of all stocks, UNCY is a bad performer in the overall market: 87.68% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to UNCY. UNCY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months UNCY reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 40.8% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -62.47% | ||
ROE | -86.52% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 82% to UNCY. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 68.07% and a revenue growth -100% for UNCY